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Copyright © 2009 JCBN Summary The quantification of urinary oxidized tyrosines, dityrosine (DiY), nitrotyrosine
(NY), bromotyrosine (BrY), and dibromotyrosine (DiBrY), was accomplished by quadruple
liquid chromatography-tandem mass spectrometry (LC/MS/MS). The sample was partially
purified by solid phase extraction, and was then applied to the LC/MS/MS using multiple-
reaction monitoring (MRM) methods. The analysis for the DiY quantification was done first.
The residual samples were further butylated with n-butanol/HCl, and the other modified
tyrosines were then quantified with isotopic dilution methods. MRM peaks of the modified
tyrosines (DiY, NY, BrY, and DiBrY) from human urine were measured and the elution times
coincided with the authentic and isotopic standards. The amounts of modified tyrosines in
healthy human urine (n = 23) were 8.8 ± 0.6 (DiY), 1.4 ± 0.4 (NY), 3.8 ± 0.3 (BrY), and 0.7 ± 0.1
(DiBrY) µmol/mol of creatinine, respectively. A comparison of the modified tyrosines with
urinary 8-oxo-deoxyguanosine, pentosidine, and Nε-(hexanoyl)lysine was also performed.
Almost all products, except for NY, showed good correlations with each other. The amounts
of the modified tyrosines (NY, BrY, and DiBrY) in the diabetic urine were higher than those
in the urine from healthy people.
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Introduction
Oxidative stress may be involved in the initiation and/or
progression of various diseases. For example, the patho-
genesis of diabetic complications is known to involve
oxidative stress [1]. Sources of reactive oxygen species
(ROS) include the Maillard reaction products [2, 3] as well
as the activated inflammatory system [4]. ROS cause
modification of biomolecules such as proteins, lipids, and
nucleic acids. The monitoring of oxidatively degraded
biomolecules, which can become oxidative stress bio-
markers, may act as an alarm/warning for the presence of
diseases like diabetes. To monitor these markers, human
urine is one of the most suitable sources for non-invasive
sampling without inducing pain.
The oxidative modification of proteins often induces
structural damage to amino acid residues [5,  6]. Of the
twenty amino acids, tyrosine is a unique target for oxidizing
species because the profiles of the tyrosine oxidation pro-Y. Kato et al.
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ducts are different from ROS. For example, 3-nitrotyrosine
(NY) is a marker for reactive nitrating species such as
peroxynitrite and NO2− [7, 8], which originate from excess
nitric oxide (·NO); NO should be generated from nitric oxide
synthase. Therefore, NY may be a marker of activated
macrophages. The halotyrosines, 3-chlorotyrosine (ClY)
and 3-bromotyrosine (BrY), appear to be markers of inflam-
matory tissue damage because eosinophil peroxidase (EPO)
and neutrophil myeloperoxidase (MPO) generate haloge-
nating species such as HOCl/HOBr [9–13]. Dityrosine
(DiY) is one of the cross-linkers of proteins. DiY can thus
become one of the universal protein oxidation markers
because DiY can be generated by various ROS, such as
peroxynitrite (ONOO−), metal-catalyzed oxidation, and UV-
irradiation [14]. These products that originate from tyrosine
may serve as oxidative stress biomarkers (Scheme I).
Immunochemical approaches have been used to detect the
modified tyrosines NY, DiY, and ClY. Antibodies to NY
have been prepared and are widely used for immuno-
histochemical staining, enzyme-linked immunosorbent assay
(ELISA), and Western blot analysis [15]. DiY has been
immunochemically identified in the lipofuscin of pyramidal
neurons in the aged human brain [16] and in atherosclerotic
lesions in Apo-E deficient mice [17]. Positive staining of
DiY has been reported in models of Alzheimer and
Parkinson diseases [18,  19]. The antibody to ClY was
recently prepared and used in immunohistochemical staining
[20, 21]. The preparation of an antibody recognizing di-
halotyrosines (both dichloro- and dibromotyrosines) has
also been done and the positive immunostaining of the liver
of lipopolysaccharide (LPS)-treated mice has already been
described [22]. Although these immunochemical approaches
can visually show the localization of modified tyrosines,
this method is not suitable for the “rigid” quantification and
chemical identification of the modified tyrosines.
To estimate the exact amount of these tyrosine-derived
products, gas-chromatography mass spectrometry (GC/MS)
and high performance lipid chromatography (HPLC)-
electrochemical detection (ECD) have been used [23–25].
Urinary DiY has also been quantified by GC/MS [26] and
by tandem liquid chromatography-mass spectrometry (LC/
MS/MS) [27]. A more recent study has reported the simulta-
neous quantification of DiY, including other modified
tyrosines in urine using LC/MS/MS [28]. NY has also been
quantified by GC-MS, HPLC-ECD, and LC/MS/MS [24, 25,
29, 30]. To avoid the artificial generation of NY, GC/MS in
the negative ion chemical ionization mode has been applied
[31]. Halotyrosines, such as ClY, BrY, 3,5-dichlorotyrosine
(DiClY), and 3,5-dibromotyrosine (DiBrY), have also been
detected in tissues using GC/MS [9, 13, 32–34]. ClY and
BrY in human urine have been detected by GC/MS [35].
However, there are few reports on the simultaneous quantifi-
cation of these several modified tyrosines [28].
In this study, we serially and simultaneously quantified
the modified tyrosines and other oxidative stress markers
(including advanced glycation end-products [AGEs] and an
oxidized nucleoside) in the urine of healthy controls.
Moreover, as a preliminary study, we compared the levels
of modified tyrosines between healthy controls and people
with diabetes.
Scheme I. Generation of tyrosine-derived modified productsEstimation of Oxidatively Modified Tyrosines in Human Urine
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Materials and Methods
Materials
3-Nitrotyrosine (NY) and 3-chlorotyrosine (ClY) were pur-
chased from Sigma Chemical Company. 3,5-Dibromotyrosine
(DiBrY) was prepared as described below and also obtained
from Aldrich. N-Bromosuccinimide (NBS), tyrosine, sodium
hypochloride (NaOCl), and other reagents were purchased
from Wako Chemicals Co., Ltd. Stable isotopic tyrosines,
[13C6]tyrosine and [13C9]tyrosine, were obtained from
Cambridge Isotope Laboratories, Inc.
Synthesis of modified tyrosines
Synthesis of DiY was done as previously reported [36].
Briefly, L-tyrosine (5 mg) was incubated for 1 h with 75 μg
of horseradish peroxidase (HRP) in the presence of 5 μl of
30% H2O2 in 5 ml of 0.1 M borate buffer (pH 9.0). The
mixture was acidified by the addition of 500 μl of 6 N HCl
and 100 μl of trifluoroacetic acid (TFA) and then applied to
a solid phase extraction (SPE) column (Supelco Spelclean
ENVI-18, 500 mg solid). The column was then washed with
2 ml of 0.1% TFA, and the sample was eluted with 1 ml of
0.1% TFA/CH3OH (1:3). The eluate was concentrated and
then further purified by reversed-phase HPLC [36]. BrY and
DiBrY were simultaneously prepared by treating L-tyrosine
(2 mM) with 2 mM of NBS in water. The reaction was
terminated by the addition of L-methionine (final concentra-
tion 3 mM). The crude reaction mixture was acidified by the
addition of a bolus of TFA solution. The reaction mixture
was then applied to an SPE ENVI-18 column, which was
washed with 2 ml of 0.1% TFA, and the sample was then
eluted with 2 ml of CH3OH. BrY and DiBrY in the eluate
were concentrated and further purified by reversed-phase
HPLC using Develosil ODS-HG-5 (8 × 250 mm) equili-
brated with 0.1% acetic acid/CH3CN at a flow rate of
2 ml/min. In addition, commercially-obtained DiBrY was
also used. DiClY was prepared from N-acetyl-tyrosine
(NAY) in several steps [22]. NAY (2 mM) was chlorinated
by exposure to 2 mM NaOCl in 0.1 M phosphate buffer
(pH 7.4) for 24 h at room temperature. The reaction was
terminated by the addition of 5 mM L-methionine. The reac-
tion mixture was concentrated by freeze-drying and N-
acetyl-3,5-dichlorotyrosine (NADiClY) in the sample was
purified by reversed-phase HPLC. The sample was applied
to the ODS-HG-5 (8 × 250 mm) using 0.1% TFA/CH3OH
(1:1) at a flow rate of 2.0 ml/min, and the peak was collected
and further purified. The purified NADiClY was then
hydrolyzed by 6 N HCl at 105°C for 24 h. The generated
DiClY was purified by reversed phase HPLC using the
ODS-HG-5 (8 × 250 mm) with 0.1% acetic acid/CH3OH
(7:3) as the eluent at a flow rate of 2.0 ml/min. The concen-
tration was estimated by quantification of the amino residues
using trinitrobenzenesulfonic acid (TNBS) [37].
As internal standards, stable isotopic DiY ([13C18]DiY)
was prepared from [13C9]tyrosine by treatment with HRP and
H2O2, and then purified as described above. To prepare the
isotopic mono- and di-bromotyrosines, [13C9]tyrosine was
modified by NBS as described above and the formed
bromotyrosines were purified by HPLC. To prepare the iso-
topic mono- and di-chlorotyrosines, N-acetyl-[13C9]tyrosine
was prepared first. Briefly, [13C9]tyrosine (70 μM) was
acetylated by acetic anhydrate (0.36 mM) in a saturated
sodium acetate solution for 24 h at room temperature. The
sample was partly purified using the SPE column (ENVI-18,
500 mg), which was then washed with 1 ml of 0.1% TFA
and eluted with 3 ml of CH3OH. The eluate was concen-
trated and purified by reversed phase HPLC using an ODS-
HG-5 (8 × 250 mm) with 0.1% TFA/CH3OH (75:25) at a
flow rate of 2.0 ml/min by monitoring at UV 215 nm. The
N-acetyl-O-acetyl-[13C9]tyrosine obtained was treated for
24 h with 0.1 M borate buffer (pH 9.0) to remove the O-
acetyl moiety and the resulting N-acetyl-[13C9]tyrosine was
purified by reversed phase HPLC using the ODS-HG-5
(8 × 250 mm) with a solvent of 0.1% acetic acid/CH3OH
(7:3) at a flow rate of 2.0 ml/min. The purified stable
NAY was further modified by NaOCl as described above.
After purifying the chlorinated N-acetyl-[13C9]tyrosines
by HPLC, N-acetyl-[13C9]chlorotyrosine and N-acetyl-
[13C9]dichlorotyrosine were de-acetylated by acid hydrolysis,
and further purified as described above. [13C9]NY was
synthesized by treating [13C9]tyrosine with peroxynitrite.
Briefly, peroxynitrite was prepared as previously described
[38, 39]. The tyrosine (0.2 mg/ml) was reacted with 1 mM
peroxynitrite in 0.1 M phosphate buffer containing 1 mM
Fe/ethylenediaminetetraacetic acid (EDTA) (pH 7.4) [15].
The reaction mixture was acidified by the addition of TFA
and then applied to a solid-phase extraction (SPE) column
(ENVI-18). The SPE column was washed with 2 ml of 0.1%
TFA and then eluted with 2 ml of 0.1%TFA/methanol (1:1).
The eluate was collected and further purified by reversed-
phase HPLC using the ODS-HG-5 (8 × 250 mm) with the
solvent 0.1% acetic acid/CH3OH (7:3) at a flow rate of
2.0 ml/min by monitoring at UV 274 nm.
Sample preparation
Human urine was collected as a spot sample after approval
by the Nakatsugawa Municipal Hospital committee. The
urine was frozen at −70°C until use. The sample was dis-
solved and centrifuged to remove any insoluble materials.
The supernatant was collected and 300 μl of the sample was
used for the analysis of the modified tyrosines. An internal
standard cocktail (containing 500 nM of [13C6]tyrosine and
50 nM of [13C9]DiY, [13C9]ClY, [13C9]DiClY, [13C9]NY,
[13C9]BrY, and [13C9]DiBrY) was added to the sample and
the proteins in the urine were precipitated by 0.1% TFA and
10% trichloroacetic acid (TCA). The sample was centri-Y. Kato et al.
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fuged to remove the proteins and the supernatant underwent
solid phase extraction (ENVI-18 [500 mg]), which had been
preconditioned by 2 ml of methanol, followed by 6 ml of
0.1% TFA. The SPE column was washed by 3 ml of 0.1%
TFA and the sample was eluted in three 750 μl aliquots of
0.1% TFA/methanol (2:3). The combined eluate (approx.
2.25 ml) was concentrated by centrifugal evaporation, and
the dried sample was dissolved in 250 μl of 2 mM
ammonium formate and analyzed by LC/MS/MS as
described below. As another method to remove urinary
proteins, CH3CN (9:1) was added to the urine and the
sample was centrifuged. The upper layer was evaporated
using a centrifugal evaporator, dissolved in 0.1% TFA and
applied to an ENVI-18 SPE column. While a previous report
showed the possibility of an artifact generation of NY by
acid plus nitrite [40], NY formation by TCA precipitation
could not be confirmed in our urine samples.
First LC/MS/MS analysis for tyrosine and dityrosine
(Method I)
The SPE-purified urine (10 μl) was analyzed twice using
an electrospray-ionization quadruple tandem mass spectro-
meter (API-3000, Applied Biosystems Co.) connected to an
Agilent 1100 HPLC system. Data were calculated from the
averages of two serial analyses of one sample. For the DiY
and tyrosine analyses, HPLC was done by gradient systems
using solvent A (0.1% acetic acid) and solvent B (CH3CN).
The separation was performed using the ODS-HG-3
(2 × 50 mm). The gradient program is as follows: 0 min
(A100%), 2 min (A100%), 7 min (A50%), 7.1 min (A100%),
15 min (A100%). The positive mode was used for the
electrospray ionization (ESI). To reduce possible contamina-
tion of the ion source, the flow was separated by a Valco
switching valve using the following program: 0 min (waste),
2 min (mass), 7 min (waste). The four multiple reaction
monitoring (MRM) transitions used for the DiY were as
follows: 379.2/332.1 (internal standard, [13C18]DiY-1),
379.2/253.1 (internal standard, [13C18]DiY-2), 361.2/315.1
(native DiY-1), and 361.2/237.1 (native DiY-2). The two
MRM combinations for one molecule showed a similar
sensitivity. The use of two MRMs on one molecule is
meaningful for the identification of DiY. To estimate urinary
tyrosine, the analyte was diluted 100-fold by a solution
of 2 mM ammonium formate with an additional internal
standard (500 nM of [13C6]tyrosine) and then analyzed
separately. Two MRMs 182.2/136.1 (tyrosine) and 188.1/
142.1 ([13C6]tyrosine) were used for the analysis. To check
for artifact formation of DiY during sample preparation,
the MRM of the [13C6]tyrosine-derived DiY was also
determined regularly. A summary of the MRM scan settings
is listed in Table 1. To avoid a decrease in the S/N ratio, the
MRM scan program for the [13C6]tyrosine-derived DiY
was omitted in routine analyses.
Second LC/MS/MS analysis for butylated modified tyrosines
(Method II)
The rest of the DiY analysis was used for analysis of
butylated modified tyrosine. The sample, which had already
been enriched with the stable isotopes, was recovered in a
glass tube and concentrated by centrifugal evaporation. The
dried sample was butylated with 500 μl of n-butanol/HCl
(2:1) at 65°C for 30 min. The sample was again evaporated
by centrifugal evaporation and then dissolved with 200 μl of
0.05% formic acid/CH3CN (95:5). The HPLC was done by
gradient systems using 0.05% formic acid (solvent A) and
CH3CN (solvent B). The separation was performed using
the ODS-SR-5 (2 × 150 mm), with a gradient program as
follows: 0 min (A80%), 2 min (A 80%), 22 min (A70%),
23 min (A50%), 25 min (A50%), 25.1 min (A80%), and
35 min (A80%). The positive mode was used for the
ionization. Twenty MRM transitions, which were derived
from the liberation of the butyl moiety, were used for the
analysis. The switching valve was set as follows: 0 min
(waste), 3 min (mass), 20 min (waste). To check the artifact
formation of the modified tyrosines during sample prepara-
tion, the MRM of the modified [13C6]tyrosines was also
determined. A summary of the MRM scan settings for
butylated samples is listed in Table 2.
Addition and recovery experiments
The coefficient of variance (CV) was estimated using 12
urine sample that were enriched with 50 nM of authentic
modified tyrosines. The samples were processed and
analyzed by LC/MS/MS as described above. Estimation of
the recovery of the added modified tyrosines was done as
follows. The authentic modified tyrosines (final concentra-
tion 0.325, 0.651, 1.30, 2.60, 5.21, 10.4, 20.8, 41.7, 83.3,
167, 333 nM) were added into the urine samples and then
processed for the LC/MS/MS analysis as described above.
Table 1. Conditions for urinary dityrosine and tyrosine analyses
by LC/MS/MS
* Asterisks show omission of setting for actual routine analysis.
Sample Q1 Q3
Scan time 
(msec)
Tyr 182.2 136.1 150
[13C6]Tyr 188.1 142.1 150
DiY-1 361.2 237.1 150
[13C18]DiY-1 379.2 253.1 150
[13C12]DiY-1* 373.2 327.1 150
DiY-2 361.2 315.1 150
[13C18]DiY-2 379.2 332.1 150
[13C12]DiY-2* 373.2 249.1 150Estimation of Oxidatively Modified Tyrosines in Human Urine
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Estimation of other biomarkers
Urinary 8-oxo-deoxyguanosine (8-Oxo-dG) was deter-
mined using an ELISA kit (JAICA, Nikken Zeil Co.). It has
been reported that the heating procedure of frozen urine
improves the recovery of urinary 8-Oxo-dG [41]. Because
we could not obtain constant results by the heating, the
supernatant of centrifuged urine without heat was used
for the estimation of urinary 8-Oxo-dG. MRX (Maillard
Reaction Product X) and pentosidine in the urine were
determined by an HPLC-fluorescence method [42]. Urinary
creatinines were determined by the Creatinine Test Wako
(WAKO Pure Chemicals). Urinary Nε-(hexanoyl)lysine
(HEL) was estimated by LC/MS/MS as described elsewhere
[43, 44].
Statistical analysis
Values (urinary biomarkers/creatinine) are expressed as
means ± SEM. Spearman’s rank correlation was used to
evaluate the relationship between the two biomarkers.
Comparisons between two groups were made using the
Mann-Whitney test.
Results
To develop the detection method of trace amounts of
urinary modified tyrosines by LC/MS/MS with stable isotopic
methods, the pattern of the collision-induced dissociation
was investigated by infusion analysis of authentic modified
tyrosines. To prevent the artificial conversion of the isotopic
internal standard of tyrosine into the isotopic modified
tyrosine, we used [13C6]tyrosine as the internal standard for
the tyrosine analysis itself, and [13C9]tyrosine was used as
the parent molecule for the synthesis of the six stable
modified tyrosine isotopes. Several fragments, which
occurred owing to the collision-induced fragmentation of
DiY, were observed [45]. Of these, the combination of
Q1/Q3 ions, 361/273 (for stable DiY) and 361/315 (for
native DiY) are similar and have a good sensitivity. The
detection limit of DiY was 1 nM and the calibration curve
of DiY was linear (R = 0.999) over a concentration range
of 1–300 nM. Using the selected MRM transitions, the DiY
in human urine was estimated by the LC/MS/MS. DiY in
some urine samples cannot be determined owing to
contaminants in the urine as described elsewhere [28].
Therefore, before the LC/MS/MS analyses, the urine
samples were uniformly purified by solid-phase extraction
(SPE). The DiY in all the SPE-treated urines can be detected
by the mass spectrometer (a typical chromatogram is shown
in Fig. 1). The CV for supplemented 50 nM DiY into the
urine was 2.4% and the recovery of authentic DiY in the
urine was significantly high (R = 0.998). We called the
determination methods as “Method I” and the MRM
combination is shown in Table 1. Because we did not
prepare the standards of the [13C6]tyrosine-derived modified
tyrosines including [13C12]DiY, the accurate quantification
of these modified products, which have a backbone of
[13C6]tyrosine, could not be done. The artifact DiY
([13C12]DiY) was observed at very low levels on the MRM
chart. For tyrosine and the other modified tyrosines,
including stable isotopes, the estimated MRM combinations
are derived from the liberation of HCOOH (−46) from the
precursor ions. For example, the MRMs 182.1/136.1 for the
native and 188.1/142.1 for the stable isotope tyrosine,
[13C6]tyrosine, were used to quantify tyrosine levels. By
checking the formation of the [13C6]tyrosine-derived
modified tyrosine, artifact generation of the modified
tyrosine can be examined during sample preparation. We
attempted the quantification of NY and halogenated
tyrosines (such as ClY and BrY) in urine by Method I.
However, the free halotyrosines could not be determined in
the SPE-treated human urine. NY cannot be clearly detected
Table 2. Conditions for butylated urinary NY, ClY, BrY, DiClY,
and DiBrY analyses by LC/MS/MS
* Asterisks (*) show omission of setting for actual routine analysis.
Butylated Sample Q1 Q3
Scan time 
(msec)
NY 283.2 181.0 30
[13C9]NY 292.5 189.0 30
[13C6]NY* 289.2 187.0 30
35ClY 272.2 170.0 30
[13C9]35ClY 281.0 178.0 30
[13C6] 35ClY* 278.2 176.0 30
37ClY 274.2 172.0 30
[13C9]37ClY 283.0 180.0 30
79BrY 316.0 214.0 30
[13C9]79BrY 325.0 222.0 30
[13C6] 79BrY* 322.1 220.0 30
81BrY 318.0 216.0 30
[13C9]81BrY 327.0 224.0 30
[13C6] 81BrY* 324.1 222.0 30
35Cl ￿ 35ClY 306.1 204.0 30
[13C9]35Cl ￿ 35ClY 315.0 212.0 30
[13C6] 35Cl ￿ 35ClY* 312.1 210.0 30
79Br ￿ 79BrY 394.0 292.0 30
[13C9]79Br ￿ 79BrY 403.0 300.0 30
[13C6] 79Br ￿ 79BrY* 400.0 298.0 30
79Br ￿ 81BrY 396.0 294.0 30
[13C9]79Br ￿ 81BrY 405.0 302.0 30
[13C6] 79Br ￿ 81BrY* 402.0 300.0 30
81Br ￿ 81BrY 398.0 296.0 30
[13C9]81Br81BrY 407.0 304.0 30
[13C6] 81Br81BrY* 404.0 302.0 30Y. Kato et al.
J. Clin. Biochem. Nutr.
72
because of a co-eluting contaminating large unknown
product, which has the same signal of MRM 227.2/181.2
for NY (data not shown).
To detect the NY and halotyrosines, the rest of DiY
analyte, which included the stable internal standards
mixture, was further derivatized by butanol/HCl, and the
successive butylated tyrosines were analyzed by LC/MS/MS
(Method II) as described in the Materials and Methods
section. To evaluate the artifact formation of the modified
tyrosines, butylated modified tyrosines with a [13C6] ring
were analyzed. The characteristic collision-induced frag-
mentations caused by the liberation of the butyl moiety
(−102 for native, −103 for stable internal standard) were
used for the MRM transmission of all the analyses for the
butylated modified tyrosines [27]. The detection limits
were approximately 0.1 nM (ClY and DiBrY), 0.3 nM (BrY,
DiClY), and 1 nM (NY). Calibration curves of Method II
were linear (R>0.99) over a concentration range of 1–
300 nM for NY, 0.1–300 nM for ClY, 0.3–300 nM for BrY,
and 0.1–300 nM for DiBrY. Using Method II, NY, BrY, and
DiBrY in the urine were successfully determined simulta-
neously (Figs. 2–4 and Table 2). Urinary NY was detected
without interference from any unknown contaminants. Each
MRM peak was co-eluted with the “partner” internal
standard which have a [13C9] backbone. Moreover, the
difference in the natural existence ratio of isotopes for 79Br
and 81Br (1:1) was also used for identification. Because BrY
has one Br atom with an equal ratio of 79Br:81Br, 79BrY and
81BrY show a similar intensity (Fig. 3). DiBrY shows a
unique mass profile of three major isotopic peaks (triplet
peak, 1:2:1) because DiBrY consists of 79Br￿79BrY,
79Br￿81BrY, and 81Br￿81BrY. Whereas a similar analogy of
the isotope ratio is applicable to the identification of
chlorotyrosine (ClY), ClY could not be clearly detected
from all samples, as successful detection of ClY was
dependent on the behavior of the samples. DiClY could not
be detected in most samples. It seems likely that the urinary
modified tyrosines are excreted as conjugates such as
glucuronide conjugates. However, the treatment of a urine
sample with β-glucuronidase/sulfatase had no effect on the
level of the modified tyrosines (unpublished observation).
The recovery of the additional authentic NY, ClY, DiClY,
BrY, and DiBrY was also estimated (NY, R = 0.999; ClY
0.991; DiClY, 0.999; BrY, 0.995; DiBrY, 0.998). The CV
Fig. 1. DiY in SPE-treated urines was separated by HPLC and
then detected using a mass spectrometer. The sample
preparation was done as described in the Materials and
Methods section. The analysis of the mass spectra was
done by “Method I”. The final concentration of the
internal standards cocktail including [13C18]DiY is 50 nM.
The MRMs of 361.2/315.1 and 361.2/237.1 show the
native DiY and those of 379.2/332.1 and 379.2/253.1
derived from the stable internal standard of DiY.
Fig. 2. MRM analysis of butylated NY from urine. The sample
preparation was done as described in the Materials and
Methods section. The analysis of the mass spectra was
done by “Method II”. Briefly, the rest of the DiY
analysis was further derivatized as butylated amino acids
and then analyzed by LC/MS/MS. The final concentra-
tion of the internal standards cocktail including [13C9]NY
is 50 nM. The MRMs of 283.2/181.0 show the native
NY and the combination of 292.5/189.0 indicate the
MRM of the stable internal standard of NY.Estimation of Oxidatively Modified Tyrosines in Human Urine
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(%) of the 50 nM standards into the urine were 4.9 (NY), 2.9
(ClY), 4.5 (DiClY), 4.7 (BrY), and 5.1 (DiBrY). The
addition of phenol to the urine prior to sample preparation
had no effects on the amount of the modified tyrosines (data
not shown), suggesting that artifact generation during
sample preparation is negligible.
First, we analyzed the urine from healthy adults (n =2 3 ,
Table 3) using Methods I and II, and correlations between
several tyrosine-derived products were examined. We also
determined the amounts of urinary 8-Oxo-dG and Nε-
(hexanoyl)lysine (HEL) [43, 44]. Urinary pentosidine and
MRX [41], which are advanced glycation end-products,
were also determined. The levels of urinary 8-Oxo-dG, HEL,
pentosidine, and MRX were 8.8 ± 0.9, 2.3 ± 0.2, 17.0 ± 0.9,
and 539 ± 70 μmol/mol of creatinine, respectively. The
amounts of the modified tyrosines in healthy human urine
(n = 23) were 8.8 ± 0.6 (DiY), 1.4 ± 0.4 (NY), 3.8 ± 0.3
(BrY), and 0.7 ± 0.1 (DiBrY) μmol/mol of creatinine. The
relationship between each modified tyrosine and the other
biomarkers are summarized in Table 4. Of the modified
tyrosines examined, DiY was significantly correlated with
BrY, DiBrY, HEL, 8-Oxo-dG, pentosidine, and MRX
(p<0.01). NY was not correlated with the other markers,
suggesting that the in vivo mechanism of NY production is
quite different. Urinary 8-Oxo-dG was significantly corre-
lated with urinary HEL, DiY, BrY, DiBrY, and pentosidine
(p<0.01), and urinary HEL was significantly correlated
Fig. 3. MRM analysis of butylated BrY from urine. The sample
preparation and analysis were done as described in the
Figure 2 legend. The final concentration of internal
standards cocktail including [13C9]BrY is 50 nM. The
MRMs of 316.0/214.0 and 318.0/216.0 show the native
79BrY and 81BrY, respectively. The MRM combination of
325.0/222.0 and 327.0/224.0 indicates the stable internal
standard of 79BrY and 81BrY, respectively.
Fig. 4. MRM analysis of butylated DiBrY from urine. The sam-
ple preparation and analysis was done as described in the
Figure 2 legend. The final concentration of the internal
standards cocktail including [13C9]DiBrY is 50 nM. The
MRMs of 394.0/292.0, 396.0/297.0 and 396.0/294.0
show the native Di79BrY, Di79/81BrY and Di81BrY, respec-
tively. The MRM combination of 403.0/300.0, 405.0/
302.0 and 407.0/304.0 indicates the stable internal stan-
dard of Di79BrY, Di79/81BrY, and Di81BrY, respectively.
Table 3. Baseline characteristics of healthy control subjects
Healthy Control (n = 23)
Age year (maen ± SD) 54.1 ± 11.0
Male/female sex 16/7
Smorkers 7Y. Kato et al.
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with urinary DiY (p<0.01), DiBrY (p<0.05), 8-Oxo-dG, and
pentosidine (p<0.01). Pentosidine and MRX were also
significantly correlated (p<0.01). In addition, there were no
significant changes in the amounts of modified tyrosines in
urines by aging or smoking status.
Next, we investigated the effects of diabetes on the
generation of these modified tyrosines. People with diabetes
(without nephropathy, n = 12) were selected for this pilot
study because it is known that the disease is associated with
oxidative stress. The concentration of the modified tyrosines
was corrected for urinary creatinine. The three markers, NY,
BrY, and DiBrY, were significantly increased in diabetic
urine compared with the healthy controls (Fig. 5). When the
modified tyrosine per tyrosine was calculated, the tendency
was similar to the creatinine correction. However, the value
from the tyrosine correlation varied widely compared with
creatinine correction.
Discussion
The estimation of urinary modified tyrosines would be a
useful tool for the evaluation of the oxidation/reduction
balance in our body. Indeed, we found differences in the
urinary modified tyrosines between healthy people and
people with diabetes. Diabetic complications are commonly
associated oxidative stress [1]. The simultaneous determina-
tion of DiY, halotyrosines, and NY should show a “profile”
of oxidative stress. We have also examined the effect of cocoa
drink on the contents of urinary modified tyrosines [46].
The simultaneous determination of modified tyrosines,
DiY and NY, in human urine by HPLC-atmospheric pressure
chemical ionization tandem mass spectrometry (HPLC-
APCI-MS/MS) has been reported [28]. The determination
was carried out without a pretreatment. However, DiY in
some samples (2–3 of eight) could not be determined by this
method. Moreover, NY and ClY could not be determined in
intact urine. A recent report described an immunoaffinity
LC/MS/MS method to measure free 3-NY in various bio-
logical fluids at very low levels [47]. However, that method
will be difficult to apply for simultaneous determination
of several modified tyrosines because the method needs
specific antibodies to each modified tyrosine. We have also
found that modified tyrosines, except for DiY, could not be
detected by LC/MS/MS using urine without the derivatiza-
tion step in our Method I. Butylation of the samples resolved
this problem, except for the detection of the urinary ClYs.
Levels of DiY, NY, BrY, and DiBrY were successfully
quantified by our serial and simultaneous Methods I–II in all
of the urine samples examined. Our HPLC-ESI-LC/MS/MS
methods required several processes including protein
precipitation, solid phase extraction, and further additional
Table 4. Correlation efficient between (glyco-)oxidative biomarkers
* p<0.05, ** p<0.01
DiY NY BrY DiBrY HEL 8Oxo Pentos MRX
DiY 1
NY 0.188 1
BrY 0.773** 0.017 1
DiBrY 0.696** −0.061 0.722** 1
HEL 0.657** 0.196 0.353 0.512* 1
8Oxo 0.743** 0.036 0.559** 0.696** 0.643** 1
Pentos 0.923** 0.015 0.677** 0.587** 0.673** 0.621** 1
MRX 0.607** 0.071 0.399 0.596** 0.286 0.388 0.587** 1
Fig. 5. Comparison of urinary DiY, NY, BrY, and DiBrY
between the control person and diabetics. The evaluation
of urines from the control (Cont., n = 23) and diabetics
(D. M., n = 12) was performed as described in the
Materials and Methods section. Comparisons between
the two groups were done using the Mann-Whitney test.Estimation of Oxidatively Modified Tyrosines in Human Urine
Vol. 44, No. 1, 2009
75
derivatization. We determined DiY separately without any
derivatization because it is difficult to control the incorpora-
tion of the butyl moiety in a DiY, which has two COOH
terminals [27]. It has been reported that DiY, NY, and o-Tyr
in cat urine could be quantified by butylation of samples
using HPLC-ESI-(quadruple)MS/MS and a quadruple/time
of flight (Q-TOF) tandem MS [27]. Using our methods, ClY
and DiClY were not completely determined in human urine
samples, but the BrYs were. The ClYs (especially DiClY)
were below the detection limit in some urine samples,
probably because the amount of BrY in human urine is about
10-times higher than that of ClY [35].
In this research study, we detected urinary DiY, NY, BrY,
and DiBrY and simultaneously quantified their levels using
quadruple mass spectrometry with liquid chromatography.
The determination of these modified tyrosines has been
performed by GC/MS [24, 25, 31]. Recently, Mita et al.
detected ClY and BrY in 2 ml of human urine by GC/MS
[35]. They reported that the urinary BrY is 22.6 ± 10.8 ng/
mg of creatinine, which can be converted into about 8 μmol/
mol of creatinine. On the other hand, we found that the
urinary BrY is 3.8 ± 0.3 μmol/mol of creatinine. Our
methods require only 300 μl of urine for determination of
the four modified tyrosines. The concentration of (non-
septic) human control urinary DiY has been shown to be
approximately 3.9 ± 1.0 μmol/mol of creatinine by GC/MS
[48]. It has also been shown that urinary DiY is 5.8 ± 0.3
µmol/mol of creatinine (morning urine) or 12.5 ± 5 µmol/mol
of creatinine (first following urine) by HPLC-APCI-MS/MS
[28]. The same group also showed that the mean urinary
DiY concentration was 10.1 ± 0.4 μmol/mol of creatinine
[49]. We detected DiY at a concentration of 8.8 ± 0.6
μmol/mol of creatinine in the control human urine. The
quantification of DiY and NY were also reported as 22.0 to
49.1 DiY/creatinine (µmol/mol) and 0.1 to 0.4 NY/creatinine
(μmol/mol) in cat urine by LC/ESI-MS/MS [27].
Peroxidases, such as MPO, can modify the tyrosine
moiety to DiY [50]. Metal-catalyzed oxidation systems are
also considered to be a plausible generator of DiY [51–57].
Peroxynitrite leads to the formation of DiY as well as 3-NY
[14] and photo-oxidation is also a plausible source for DiY
generation [36]. In this study, urinary DiY was significantly
correlated with the various markers examined. These results
may indicate that DiY is one of the important universal
biomarkers of oxidative stress. The enhancement of DiY in
urine samples in people from people with diabetes has been
reported [58]. However, in our study, no statistical difference
in DiY was observed but the urinary DiY tended to increase
in people with diabetes. In addition, we found that the
urinary DiY in people with diabetes (n = 12) is significantly
higher than in healthy controls (n = 41) (p<0.05, unpublished
observation). It has already been shown that the formation of
DiY occurs in the kidneys of diabetic Akita mice [59].
On the other hand, a nitrosative stress marker, NY, is
specifically formed by the exposure of reactive nitrogen
species (RNS) like peroxynitrite, which is derived from the
reaction between the superoxide anion radical and NO·. In
vivo, peroxidases are plausible and important players for
RNS-generation [60]. NY has already been reported to be
present in cat urine [27]. It has been reported that urinary
NY did not increase in type 1 diabetes [58]. However, we
have found enhanced NY excretion in the urine of people
with diabetes (Fig. 5). Indeed, the possibility of NY as a
useful biomarker for oxidative stress has been described [7].
The halotyrosines, ClY and BrY, are generated from
the activation of immune cells such as neutrophils and
eosinophils, which contain the peroxidases, MPO and EPO
in their granules, respectively. These enzymes generate
hypohalous acids, which can halogenate tyrosine. N-
Chloramine and Cl2 gas can also chlorinate tyrosine.
Therefore, it is difficult to identify the “true” halogenating
species in vivo. Estimation of the ratio between the amount
of ClY and BrY can not determine the contribution of
hypohalous acid (HOCl or HOBr) because of the reaction
rate of HOCl and HOBr, and its complicated reaction
mechanism [61,  62]. Although the detailed generation
mechanism of halotyrosine and the biological significance
remains unknown, halotyrosines can be considered as an
inflammatory biomarker. The amount of BrY and DiBrY in
the urine of people with diabetes was higher than that in the
control person (Fig. 5). These results indicate that the
immune system is activated in people with diabetes. The
increase in di-halotyrosines in LPS-treated mice liver
tissues has been characterized immunohistochemically using
a specific antibody to the di-halotyrosine residue [22].
Moreover, the increase in the modified tyrosines in tissue
was observed chemically and immunochemically during UV-
irradiation [63]. However, the metabolic process of excretion
of the modified tyrosine into urine is unclear [64, 65].
We have found that the relationship between urinary
biomarkers was significantly high (Table 4). This suggests
that the mechanism for the generation of the oxidative
biomarkers has something in common with each other. We
also found that the NY level was not correlated with the
levels of other modified tyrosines. This suggests that the
mechanism of NY generation is different from that of the
other modified tyrosines.
The profile of the quantification of modified tyrosines
may become a useful marker for the evaluation of oxidative
stress  in vivo. Urine is a source suitable for biological
sampling because the collection does not induce pain and is
a non-invasive process. Detailed studies of the relationship
between diabetes and modified tyrosines are now in progress.Y. Kato et al.
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